Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nonalcoholic steatohepatitis (NASH)
Pharma
Madrigal builds launch infrastructure for MASH drug Rezdiffra
Despite a reimbursement hurdle from the VA, Madrigal is still targeting 80% commercial coverage for its MASH drug Rezdiffra by year-end.
Angus Liu
May 7, 2024 11:56am
Novo, Novartis, Merck KGaA, Kyowa Kirin—Fierce Pharma Asia
Mar 22, 2024 8:45am
After MASH OK, Madrigal plots $600M stock sale to support launch
Mar 19, 2024 5:17pm
FDA approves first drug for MASH in Madrigal's Rezdiffra
Mar 14, 2024 3:56pm
Eli Lilly touts tirzepatide's midstage MASH win
Feb 6, 2024 10:35am
Big Pharma deal spree, China plans and more—Fierce Pharma Asia
Jan 5, 2024 8:44am